- ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
- Lilly and ProQR to Expand RNA Editing Collaboration
- ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022
- ProQR Announces Third Quarter 2022 Operating and Financial Results
- ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference
- ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
- ProQR Announces Second Quarter 2022 Operating and Financial Results
- ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium
- ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates
- ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022
ProQR Therapeutics NV (PRQR:NAQ) closed at 3.15, 494.34% above the 52 week low of 0.530 set on May 11, 2022.
0.530May 11 20226.15Feb 08 2022
Markit short selling activity
|Market cap||225.02m USD|
|EPS (TTM)||-1.09 |
Data delayed at least 15 minutes, as of Feb 03 2023 21:00 GMT.